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Background
Extraovarian Primary Peritoneal Carcinoma (EOPPC)
was first described by Swerdlow in 1959 [1]. Basically,
EOPPC is a malignancy that spreads widely inside the
peritoneal cavity involving mostly the omentum with
minimal or no ovarian involvement. Most of the EOPPC
cases reported have been of serous histology; histo-
pathological, immunohistochemical, and clinical similari-
ties have been observed between EOPPC and Epithelial
Ovarian Cancer (EOC).
Materials and methods
In June 2007 a 72 year-old woman was referred to our
Unit for recurrent abdominal pain, constipation, loss of
weight (BMI 17.5), serious asthenia and fever. Labora-
tory biochemistry showed hypocromic microcitic ane-
mia, leucocytosis, increased plasma levels of flogistic
markers and serious increase of CA 125 marker (373,2
U/ml – normal range 0-35 U/ml). Abdominal US scan
confirmed by CT scan (Figure 1), revealed a high vascu-
larised solid mass close to the peritoneum (maximum
diameter 10-12cm), ascites among intestinal handles and
into Douglas pouch. The colonoscopy did not show any
neoplasm. A solid mass not separable from omentum,
irregular morphology was found by median laparotomy
(Figure 2); no primary tumor was found anywhere else
in the abdomen.
Results
The morphological features such as serous papillary car-
cinoma and the presence of many psammoma bodies
and the immunohistochemical highly positive for CA
125 (Figure 3) have determined the diagnosis of EOPPC.
This patient received a first-line chemotherapeutic
treatment with paclitaxel (135mg/m
2/24 hr) and cisplatin
(75 mg/m
2) in combination for six cycles. No evidence of
recurrence was found at the 2-year follow-up.
Conclusions
As the EOPPC is mullerian malignancy as the epithelial
layer of ovary and the peritoneum share a common
embryological origin and it undergoes a chemotherapeu-
tic treatment as ovarian primary carcinoma. Paclitaxel
with platinum compounds have been introduced into
chemotherapeutic regimens for EOC. In the first report
describing the use of the combination of paclitaxel
(135mg/m
2) and cisplatin (50 to 75 mg/m
2), given for
six cycles in four EOPPC patients, Menzin et al [2]
showed a complete surgical response in one patient and
a partial surgical response in the others. Patients with
EOPPC should be reported separately from those with
ovarian carcinoma but should be treated in a similar
fashion.
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Figure 2
Figure 3 Immunoistochemical staining for the CA 125
oncoprotein: the picture shows intense membrane staining in
neoplastic cells (magnification x400).
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